Symbols

QNCX

Quince Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About QNCX

Quince Therapeutics, Inc.

A biopharmaceutical company that advancing innovative precision therapeutics for debilitating and rare diseases

Industry

Biological Technology

Established Date

06/20/2012

Listing Date

05/09/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.quincetx.com

Security Type

Common stock

Office address

611 Gateway Boulevard, Suite 273, South San Francisco, California 94080

Business

Introduction

Quince Therapeutics, Inc., was incorporated in Delaware on June 20, 2012. The company is a clinical-stage biopharmaceutical company that has pioneered a novel disease-improving treatment for what is considered a key root cause of Alzheimer's and degenerative diseases. The company's approach is based on the groundbreaking discovery of gingival porphyromonas gingivalis or P. gingivalis and its secreted toxic virulence factor proteases called gingipains in the brains of more than 100 Alzheimer's patients observed through multiple studies to date. In addition, the company has observed in animal models that Pseudomonas gingivalis infection leads to Alzheimer's pathology, and these effects have been successfully treated with gum pain inhibitors in preclinical studies. The company's proprietary lead drug candidate COR388 is an orally administered, brain-penetrating small molecule gingival pain inhibitor. COR388 has been well tolerated with no associated safety signals in the Phase 1 and Phase 1 b clinical trials conducted to date, which enrolled a total of 67 subjects, including nine patients with mild to moderate Alzheimer's disease.

Company Financials

EPS

QNCX has released its 2025 Q3 earnings. EPS was reported at -0.25, versus the expected -0.22, missing expectations. The chart below visualizes how QNCX has performed over recent quarters, highlighting trends in earnings surprises.